Inspira™ Announces Establishment of Distribution Facility to Support U.S. Deployment of INSPIRA™ ART100
Inspira Technologies (Nasdaq: IINN) has signed a distribution agreement with Glo-Med Networks to serve as its primary distributor in the United States. The agreement establishes a Florida-based distribution facility that will support the deployment of the INSPIRA ART100, which is FDA 510(k)-cleared for Cardiopulmonary Bypass procedures. The facility will provide customer support and after-market services through a partnership with Med-Stat Consulting Services. This strategic move aims to enhance operational efficiency for the planned 2024 deployment of the ART100 and future products. The company's flagship product, INSPIRA ART, targets a potential $19 billion market opportunity, aiming to serve 20 million acute respiratory failure patients annually.
Inspira Technologies (Nasdaq: IINN) ha firmato un accordo di distribuzione con Glo-Med Networks per fungere da distributore principale negli Stati Uniti. L'accordo prevede l'istituzione di una struttura di distribuzione in Florida che supporterà il lancio dell'INSPIRA ART100, che ha ottenuto la certificazione FDA 510(k) per le procedure di bypass cardiopolmonare. La struttura fornirà supporto ai clienti e servizi post-vendita attraverso una partnership con Med-Stat Consulting Services. Questo passo strategico mira a migliorare l'efficienza operativa per il lancio previsto nel 2024 dell'ART100 e dei futuri prodotti. Il prodotto di punta dell'azienda, INSPIRA ART, punta a un'opportunità di mercato potenziale di 19 miliardi di dollari, con l'obiettivo di servire annualmente 20 milioni di pazienti con insufficienza respiratoria acuta.
Inspira Technologies (Nasdaq: IINN) ha firmado un acuerdo de distribución con Glo-Med Networks para actuar como su distribuidor principal en los Estados Unidos. El acuerdo establece una instalación de distribución con sede en Florida que apoyará el lanzamiento del INSPIRA ART100, que ha recibido la aprobación 510(k) de la FDA para procedimientos de bypass cardiopulmonar. La instalación proporcionará soporte al cliente y servicios postventa a través de una colaboración con Med-Stat Consulting Services. Este movimiento estratégico tiene como objetivo mejorar la eficiencia operativa para el lanzamiento planeado en 2024 del ART100 y futuros productos. El producto insignia de la empresa, INSPIRA ART, apunta a una oportunidad de mercado potencial de 19 mil millones de dólares, con el objetivo de atender a 20 millones de pacientes con falla respiratoria aguda anualmente.
Inspira Technologies (Nasdaq: IINN)은 Glo-Med Networks와 미국 내 주요 유통업체로서의 배급 계약을 체결했습니다. 이 계약에는 심폐 우회 수술을 위한 FDA 510(k) 승인을 받은 INSPIRA ART100의 배급을 지원할 플로리다 기반의 배급 시설이 설립됩니다. 이 시설은 Med-Stat Consulting Services와의 협업을 통해 고객 지원 및 애프터 마켓 서비스를 제공할 것입니다. 이 전략적 조치는 2024년 ART100 및 향후 제품의 배급을 위한 운영 효율성을 향상시키기 위한 것입니다. 회사의 주력 제품인 INSPIRA ART는 190억 달러의 잠재적 시장 기회를 목표로 하여 매년 2천만 명의 급성 호흡 부전 환자를 서비스할 계획입니다.
Inspira Technologies (Nasdaq: IINN) a signé un accord de distribution avec Glo-Med Networks pour devenir son distributeur principal aux États-Unis. L'accord établit une installation de distribution basée en Floride qui soutiendra le déploiement de l'INSPIRA ART100, qui a reçu l'approbation FDA 510(k) pour les procédures de contournement cardiopulmonaire. L'installation fournira un support client et des services après-vente grâce à un partenariat avec Med-Stat Consulting Services. Ce mouvement stratégique vise à améliorer l'efficacité opérationnelle pour le déploiement prévu de l'ART100 en 2024 et pour de futurs produits. Le produit phare de l'entreprise, INSPIRA ART, cible une opportunité de marché potentielle de 19 milliards de dollars, visant à servir 20 millions de patients atteints d'insuffisance respiratoire aiguë chaque année.
Inspira Technologies (Nasdaq: IINN) hat einen Vertriebsvertrag mit Glo-Med Networks unterzeichnet, um als Hauptdistributor in den Vereinigten Staaten zu fungieren. Der Vertrag sieht die Einrichtung einer Vertriebsstelle in Florida vor, die die Einführung des INSPIRA ART100 unterstützen wird, das die FDA 510(k)-Zulassung für kardiopulmonale Bypass-Verfahren erhalten hat. Die Einrichtung wird Kundenunterstützung und After-Sales-Services in Partnerschaft mit Med-Stat Consulting Services anbieten. Dieser strategische Schritt zielt darauf ab, die betriebliche Effizienz für die geplante Einführung des ART100 im Jahr 2024 und zukünftige Produkte zu verbessern. Das Flaggschiffprodukt des Unternehmens, INSPIRA ART, zielt auf eine potenzielle Marktchance von 19 Milliarden US-Dollar, mit dem Ziel, jährlich 20 Millionen Patienten mit akuter Atemwegserkrankung zu betreuen.
- FDA 510(k) clearance obtained for INSPIRA ART100
- Established U.S. distribution infrastructure through Glo-Med partnership
- Large market opportunity estimated at $19 billion
- Target market of 20 million patients annually
- Products still in development phase without regulatory approval (INSPIRA ART500, Cardi-ART, VORTX, HYLA)
- Core flagship product (INSPIRA ART) not yet tested in humans
Insights
This distribution agreement marks a significant strategic move for Inspira Technologies. The establishment of a Florida-based distribution center through Glo-Med Networks represents a important operational milestone for the
The INSPIRA ART100's FDA 510(k) clearance for Cardiopulmonary Bypass procedures provides an initial market entry point, while the company positions itself for the broader deployment of its flagship INSPIRA ART device. The target market of 20 million acute respiratory failure patients annually presents substantial revenue potential.
The vertically integrated distribution and service model should enhance market penetration capabilities and customer support efficiency. However, investors should note that several key products, including the INSPIRA ART500 and HYLA blood sensor, are still in development and await regulatory approvals.
The distribution agreement demonstrates strong supply chain optimization strategy. Centralizing U.S. operations through a Florida-based facility offers several advantages:
- Reduced logistics complexity and costs
- Faster response times for customer support
- Streamlined maintenance services through Med-Stat partnership
- Enhanced inventory management capabilities
The Company has signed a distribution agreement that assigns to Glo-Med the role of Inspira's primary distributor and customer support center in the
RA'ANANA,
The distribution facility, located in
Joe Hayon, co-founder and President of Inspira Technologies, stated, "This distribution agreement represents a crucial milestone in our efforts to introduce Inspira's innovative technologies to the market. With Glo-Med managing the deployment and maintenance of the INSPIRA ART 100 system in the
Matus Knoblich, CEO of Glo-Med, stated, "I believe that the coupling of Glo-Med's distribution network and capabilities with the industry leading service provided by Med-Stat will create a fully vertically integrated business model where customers can receive the highest level of service and support within the industry sector. Both companies will be working with the same mission in mind: growth and expansion of the Inspira Technologies brand coupled with a fully supported user experience. We believe that this will lead to success for all participants."
Inspira™ Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in the life support and respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA™ ART), a groundbreaking device poised to revolutionize the
The Company's INSPIRA™ ART100 system has obtained FDA 510(k) clearance for use in Cardiopulmonary Bypass procedures, along with the Israeli AMAR certification for both Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products and technologies, including the INSPIRA ART also known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART portable modular device, VORTX orbiting Oxygen Delivery System and HYLA™ blood sensor, are currently being designed and developed, and have not yet been tested or used in humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
Contact:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
MRK-ARS-118
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo - https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-announces-establishment-of-distribution-facility-to-support-us-deployment-of-inspira--art100-302285959.html
SOURCE Inspira Technologies
FAQ
When will Inspira Technologies (IINN) deploy the INSPIRA ART100 in the US?
What regulatory approvals has Inspira Technologies (IINN) received for the INSPIRA ART100?